[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bronchiolitis-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bronchiolitis-acute":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,67,101,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100580817","descriptive-study-of-the-initial-management-of-young-children-with-moderate-acute-bronchiotitis-with-home-hospitalisation-100580817",false,"NCT06842238","Descriptive Study of the Initial Management of Young Children With Moderate Acute BRONCHiotitis With Home Hospitalisation","BRONCHAD","Inclusion Criteria:\n\n* Any infant with moderate bronchiolitis according to the HAS definition (except for the SpO2 criterion which must be greater than or equal to 92% to avoid the patient being on oxygen therapy upon admission)\n* Age \\> 2 months and ≤ 2 years\n* Respiratory syndrome for 48 hours\n* Infant with a first episode of bronchiolitis\n* Referral of the general practitioner\u002Ftreating pediatrician for home hospitalisation care\n* Parents' agreement for the choice of home hospitalisation care\n* Non-opposition or free and informed consent of both parents to the use of the child's health data\n\nExclusion Criteria:\n\n* Patient not receiving health protection\n* Comorbidities: congenital heart disease with shunt, chronic pulmonary pathology including bronchopulmonary dysplasia, neuromuscular pathology, immune deficiency, multiple disabilities Congenital heart disease\n* Refusal of one or both parents for the proposed pathway\n* Doubts about the parents' understanding of the nature of home hospitalisation care\n* Severe bronchiolitis or with saturation \\\u003C 92%\n\n  * Moderate bronchiolitis but evolving for less than 48 hours\n  * Cases of psychiatric pathologies or depressive syndrome diagnosed in the parents.","ALL","2 Months","2 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","The occurrence of a first episode of acute bronchiolitis in an infant or young child (3 months-2 years) always represents a medical event that generates stress for parents and in some cases for the primary care physician when it is necessary to decide on the child's orientation for treatment. Each year, during the winter season, this pathology affects 30% of infants under two years old (480,000 annual cases in France), generates approximately 30,000 hospitalizations and exposes to an overall mortality risk of 0.08%.\n\nAccording to the recommendations of the HAS (2019), moderate bronchiolitis does not require systematic hospitalization and can be managed in a Home Hospitalization (HAD) context.\n\nWhen the child's examination data do not find signs of severity, the SpO2 measurement is greater than 92% and the family context allows for return home, HAD management is a reasonable option and represents an alternative to the classic scheme of assessing the level of severity by the emergency department and subsequent hospitalization if necessary. HAD management is carried out within the framework of a very structured \"patient pathway\", codified and supervised by the pediatric teams and doctors of this department. This patient pathway concerns children with a moderate form of bronchiolitis without oxygen requirements at the time of inclusion. This must be 48 hours from the onset of the child's respiratory clinical signs.\n\nThe main objective of this study is to describe the need for oxygen therapy for a young child with moderate acute bronchiolitis syndrome during home hospitalization (HAD) care.",[25,26],"Bronchiolitis","Bronchiolitis Acute","RECRUITING","2026-04-20",{"date":30,"type":31},"2026-04-21","ACTUAL",{"date":33,"type":31},"2025-06-14",{"date":35,"type":21},"2027-03-14",{"name":37,"class":38},"Elsan","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100611674","i-decide-after-bronchiolitis-hospitalization-100611674","NCT07243652","I-DECIDE After Bronchiolitis Hospitalization","Cluster Randomized Trial of a Moderate vs High Resource Implementation Strategy to Increase As-needed Post-hospitalization Follow-up for Children With Bronchiolitis","I-DECIDE","Inclusion Criteria:\n\n* Primary diagnosis of bronchiolitis, discharged by a generalist inpatient service from a non-ICU, non-emergency department, non-step down unit\n\nExclusion Criteria:\n\n* Children with a history of gestational age \\\u003C28 weeks, chronic lung disease, complex or hemodynamically significant heart disease, immunodeficiency, or neuromuscular disease\n* Children being discharged with home oxygen therapy","0 Months","24 Months",{"count":51,"type":21},2700,"INTERVENTIONAL",[54],"NA","Although automatic follow-up is a nearly universal practice, research has shown that these visits are often unnecessary after hospitalizations caused by bronchiolitis. Despite endorsement by national pediatric authorities, robust evidence, and family enthusiasm for as-needed (PRN) follow-up, it remains substantially underutilized for children hospitalized for bronchiolitis.\n\nThe goal of I-DECIDE is to compare the effects of two multi-component implementation strategies, both of which aim to (a) increase PRN follow-up prescribing by hospitalists (physicians who care for hospitalized children) and (b) decrease unnecessary follow-up visit attendance by families.",[26],"2026-02-02",{"date":59,"type":31},"2026-02-04",{"date":61,"type":31},"2025-11-01",{"date":63,"type":21},"2029-12",{"name":65,"class":38},"Seattle Children's Hospital",56,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":49,"enrollmentInfo":76,"targetDuration":78,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100622297","modern-technologies-in-lower-respiratory-tract-infections-in-children-100622297","NCT07381790","Modern Technologies in Lower Respiratory Tract Infections in Children","Modern Technologies for Individual Risk Stratification in Infant Lower Respiratory Tract Infections","MoT-LRTI","Inclusion Criteria:\n\n* clinical diagnosis of lower respiratory tract infection\n* with tachypnea and\u002For\n* wheezing\n* Retractions\n* Respiratory difficulties\n\nExclusion Criteria:\n\n* Severe Congenital heart disease (not ASD, small VSD, PDA)\n* Cystic fibrosis and PCD\n* Neuromuscular diseases and other diseases with reduced airway clearance\n* Severe malacia, diagnosed by bronchoscopy by time of T0.\n* Foreign body inhalation\n* Pneumothorax\n* Pleural effusion (with need of invasive interventions)\n* Bronchopulmonary dysplasia or GA \\\u003C32 weeks\n* Caretaker not able to communicate in Norwegian or English\n* Weight \\\u003C3 kg","0 Days",{"count":77,"type":21},200,"1 Year","Lower respiratory tract infections (LRTIs) are a significant cause of childhood morbidity and mortality globally, particularly in low-income countries. In Norway, LRTIs is a leading cause of hospitalization among infants, representing a great socioeconomic burden.\n\nBronchiolitis, a viral infection, is the main representation of LRTIs in infants. It affects the small airways, causing breathing- and feeding difficulties. Today, treatment relies on subjective evaluations, lacking objective measures for assessment. This increases the risk of both under- and over treating patients. In the long term, bronchiolitis increases risk of asthma, but it is unknown who the high-risk patients for chronic lung disease are.\n\nLung ultrasonography (LUS) has emerged as a promising tool for assessing bronchiolitis severity and progression of the disease. The investigators will explore its use to improve diagnostic accuracy and treatment decisions, and develop AI-driven scoring tools for novel technology.\n\nAdditionally, tidal breathing flow volume loops (TBFVL) offer a non-invasive method for evaluating airway obstruction in infants, with the potential to assess severity of bronchiolitis, treatment efficacy and post-infection lung function.\n\nIn this project the investigators will combine the use of these modern technologies to improve treatment and follow-up of infants with LRTIs.\n\nThe main aim for this observational study is to assess the utility of lung ultrasonography (LUS) and tidal flow volume loops (TBFVL) in infant lower respiratory tract infections (LRTIs) for individual risk stratification in acute and chronic settings. This aims to refine the management of bronchiolitis, identifying high-risk patients for chronic lung disease to tailor treatment and follow-up protocols.\n\nThe project has three secondary objectives.\n\n1. To assess correlation between LUS and TBFVL findings with clinical score at admission, length of stay, need of respiratory support and ICU admissions.\n2. To assess duration of symptoms following acute bronchiolitis and evaluate the use of LUS and TBFVL in objectively examine post-infectious sequela.\n3. To evaluate the long-term impact of bronchiolitis on lung function through clinical follow-up after a 12 month period.\n\nLower respiratory tract infections (LRTIs) stand as the leading cause of hospitalization, while asthma is the leading cause of chronic lung disease among children in Nordic countries. The project seeks to improve risk stratification and treatment protocols in both acute and chronic settings.\n\nIn the acute setting, the project endeavors to prognosticate individual patient outcomes, thereby individualize treatment and mitigating unnecessary hospital admissions, use of respiratory support and antibiotic administration. Additionally there is potential of more aggressive treatment to selected patients. The study aims to improve the understanding of pathophysiological processes of LRTIs in infants, providing objective metrics to evaluate disease severity and individualize treatment.\n\nThe investigators aim to validate the utility, validity, and simplicity of handheld ultrasound devices as bedside diagnostic tools for this common disease, alongside affirming the value of tidal flow volume loops (TBFVL) in acute and chronic settings to assess airway obstruction in infants. Combining these modern technologies, evaluating affliction of both the parenchyme and the airways will probide a new perspective in treatment of LRTIs. In addition the project will strive to develop novel technology with AI-driven scoring tools of LUS.\n\nFurthermore, the project aims to examine the trajectory of symptoms post-LRTI and facilitate the early identification of patients with high-risk of chronic lung disease. Early detection of asthma and other chronic lung diseases holds the potential to improve outcomes and mitigate the need for hospitalization, thus easing both economic and emotional burdens associated with the disease.\n\nFor caregivers, the lack of information concerning symptom duration and risk of future disease represents a significant knowledge gap. The project aims to address this, by examining post-infection symptom duration and identifying high-risk cohorts predisposed to chronic lung disease. This has the potential to both improve information, personalize follow-up and reduce hospital readmissions.",[26,81,82,83,84,85],"Lower Respiratory Tract and Lung Infections","Pediatric Lung Ultrasound","Tidal Volume","Pediatric Lung Diagnosis","Pediatric Asthma",[87,88,89,90],"pediatric","lung ultrasound","lower respiratory tract infections","tidal-flow volume loops","2026-01-26",{"date":57,"type":31},{"date":94,"type":31},"2025-12-15",{"date":96,"type":21},"2029-06-30",{"name":98,"class":99},"Helse Møre og Romsdal HF","OTHER_GOV",2,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":78,"enrollmentInfo":110,"targetDuration":4,"studyType":52,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100529701","bronchiolitis-clearance-airways-with-seaserum-100529701","NCT06177197","Bronchiolitis Clearance Airways With Seaserum","Bronchiolitis Clearance Airways With Seaserum : a Doubled Blind Randomized Study","B-CLASS","Inclusion Criteria:\n\n* Infants aged more than 1 month and less than 1 year\n* First episode of acute bronchiolitis\n* Emergency consultation\n* Existence of nasal obstruction\n* Onset of symptoms \\< 48 hours before emergency consultation\n* Outpatient care after emergency consultation\n* Mild to moderate bronchiolitis according to the \\"Haute Autorité de Santé 2019\\" criteria:\n\nRespiratory rate over 1 minute \\>30\u002Fminutes and \\<60\u002Fminute ; Heart rate \\>80\u002Fminutes and \\<180\u002Fminutes; Absence of respiratory pauses; Absence of superficial breathing; Absence of signs of intense respiratory struggle: involvement of the lower intercostal accessory muscles, sternocleidomastoid muscles, thoracoabdominal swinging, or flapping of the wings of the nose; Feeding \\>50% of the usual quantity over 3 consecutive doses; SpO2 \\> 92% during sleep ; \\>94% when awake; \\>2 months corrected age\n\n* Parental consent\n* Affiliate to a social security system\n\nExclusion Criteria:\n\n* Hospitalization (excluding short stay unit) after emergency consultation\n* Oxygen therapy\n* History of prematurity (birth \\<36 weeks of amenorrhea)\n* History of invasive ventilation in the neonatal period\n* History of chronic pulmonary or cardiac pathology\n* History of immune deficiency\n* History of polyhandicap or neuromuscular pathology\n* History of malformative Ear Nose and Throat pathology affecting the upper airways\n* Impossibility of ensuring the follow-up made necessary by participation in this study","1 Month",{"count":111,"type":21},458,[54],"The objective of this study is to show that the use of electrodialyzed seawater reduces the duration (in days) of symptoms in acute infant bronchiolitis compared with the use of saline solution in infants aged 1 month to less than one year.\n\nB-CLASS study is a multicenter, prospective, controlled, randomized, double label blind.",[26],[116,117,25],"Infant","Nasopharyngeal decongestion","2025-12-16",{"date":120,"type":31},"2025-12-17",{"date":122,"type":31},"2025-01-10",{"date":124,"type":21},"2028-12-01",{"name":126,"class":38},"University Hospital, Brest",8,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":52,"phases":140,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100569083","mucociliary-clearance-techniques-for-acute-bronchiolitis-100569083","NCT06689631","Mucociliary Clearance Techniques for Acute Bronchiolitis","Efficacy of Mucociliary Clearance Techniques in Non-hospitalised Infants with Acute Bronchiolitis","CLEARBRONCH","Inclusion Criteria:\n\n* Medical diagnosis of first episode of acute Bronchiolitis.\n* Acute Bronchiolitis with mild (ESBA score = 1-4) or moderate (ESBA score =5-9) severity according to the ESBA.\n* Informed consent signed by parents or legal guardians.\n\nExclusion Criteria:\n\n* Infants previously diagnosed with chronic respiratory disease.\n* Previous episodes of wheezing.\n* Presence of any type of contraindication to receive Respiratory Physiotherapy treatment.","28 Days","12 Months",{"count":139,"type":21},70,[54],"To assess the efficacy of mucociliary clearance techniques in non-hospitalised infants with a first episode of mild to moderate acute bronchiolitis.",[143,26,144],"Acute Bronchiolitis Due to Respiratory Syncytial Virus","Bronchiolitis Acute Viral",[146,147],"mucociliary clearance","respiratory physiotherapy","NOT_YET_RECRUITING","2024-11-14",{"date":151,"type":31},"2024-11-19",{"date":153,"type":21},"2024-12-01",{"date":155,"type":21},"2025-05-31",{"name":157,"class":38},"Universidad de León"]